RHOA

Across TCGA pan-cancer cohorts, RHOA Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RHOA data layer compared with 27 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RHOA Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RHOA expression acts as an unfavorable survival marker.

OV, DLBC, and BLCA are the cancer types where RHOA Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	All	0.244	0.690	.006	18	view →
DLBC	OS	Median	All	0.136	0.885	<.001	9	view →
BLCA	OS	Median	III,IV	0.350	0.690	.012	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RHOA–OV (OS)

Open the OV breakdown →